COVID-KOSHA
Home
Help
(current)
Comment
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
High priority articles (R1, Most articles most likely to be relevant):
Second priority articles (R2, Moderate portion of articles likely to be relevant):
Other articles (R3, Lesser portion of articles likely to be relevant):
Drug Studies-in vitro
Last updated: 2024 Apr 18
Total hit(s): 1019
S.No.
PMID
Ascending order
Descending order
Title
Ascending order
Descending order
Journal Name
Ascending order
Descending order
Publish Date
Ascending order
Descending order
Impact Factor
Ascending order
Descending order
Citations
Ascending order
Descending order
Auto summary
Ascending order
Descending order
1
38086763
Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies.
J Enzyme Inhib Med Chem
2024 Dec
8.6
1
2
38550333
Investigation of phytochemicals isolated from selected Saudi medicinal plants as natural inhibitors of SARS CoV-2 main protease: In vitro, molecular docking and simulation analysis.
Saudi Pharm J
2024 May
5.6
1
3
38552631
Micro-patterned culture of iPSC-derived alveolar and airway cells distinguishes SARS-CoV-2 variants.
Stem Cell Reports
2024 Apr 9
12.2
1
4
38632023
Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021.
J Microbiol Immunol Infect
2024 Apr 7
2.33
1
5
38588829
Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2.
Eur J Pharm Biopharm
2024 Apr 6
1
6
38608595
In vitro pharmacokinetic behavior in lung of harringtonine, an antagonist of SARS-CoV-2 associated proteins: New insights of inhalation therapy for COVID-19.
Phytomedicine
2024 Apr 4
7.2
1
7
38604076
Evaluation of the SARS-CoV-2 RNA detection reagent LAMPdirect Genelyzer KIT using nasopharyngeal swab and saliva samples.
Diagn Microbiol Infect Dis
2024 Apr 4
2.33
1
8
38575586
The metabolic footprint of Vero E6 cells highlights the key metabolic routes associated with SARS-CoV-2 infection and response to drug combinations.
Sci Rep
2024 Apr 4
4.12
1
9
38617221
Distal Protein-Protein Interactions Contribute to SARS-CoV-2 Main Protease Substrate Binding and Nirmatrelvir Resistance.
bioRxiv
2024 Apr 2
- n/a -
1
10
38597182
Enteric coronavirus nsp2 is a virulence determinant that recruits NBR1 for autophagic targeting of TBK1 to diminish the innate immune response.
Autophagy
2024 Apr 16
10.79
1
11
38616133
Synergism between remdesivir and ribavirin leads to SARS-CoV-2 extinction in cell culture.
Br J Pharmacol
2024 Apr 14
6.48
1
12
38616188
Molecular modelling studies and in vitro enzymatic assays identified A 4-(nitrobenzyl)guanidine derivative as inhibitor of SARS-CoV-2 Mpro.
Sci Rep
2024 Apr 14
4.12
1
13
38508555
Identification of potential vaccine targets for elicitation of host immune cells against SARS-CoV-2 by reverse vaccinology approach.
Int J Biol Macromol
2024 Apr
4.94
1
14
38525106
Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system.
MedComm (2020)
2024 Apr
1
15
38461050
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Vaccine
2024 Mar 8
3.31
1
16
38554446
Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist.
Int Immunopharmacol
2024 Mar 29
3.38
1
17
38553521
A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.
Sci Rep
2024 Mar 29
4.12
1
18
38521982
COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance.
Med Mycol
2024 Mar 28
1
19
36415456
In-silico docking platform with serine protease inhibitor (SERPIN) structures identifies host cysteine protease targets with significance for SARS-CoV-2.
bioRxiv
2024 Mar 27
- n/a -
1
20
38520147
Discovery of small molecule entry inhibitors targeting the linoleic acid binding pocket of SARS-CoV-2 spike protein.
J Biomol Struct Dyn
2024 Mar 23
3.22
1
21
38612407
mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions.
Int J Mol Sci
2024 Mar 22
4.21
1
22
38493907
Thai traditional medicines reduce CD147 levels in lung cells: Potential therapeutic candidates for cancers, inflammations, and COVID-19.
J Ethnopharmacol
2024 Mar 15
6.8
1
23
38478629
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.
Sci Transl Med
2024 Mar 13
11.64
1
24
38472181
Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2.
Nat Commun
2024 Mar 12
11.8
1
25
38466126
In Silico and In Vitro Screening of Some Pregnane Glycosides Isolated from Certain Caralluma Species as SARS-COV-2 Main Protease Inhibitors.
Chem Biodivers
2024 Mar 11
1